SARS-CoV-2 Total Assay

Secure your community with science and scale

A total antibody assay helps give a complete picture of infection status and immune response

Smart selection of S1RBD antigen looks to the future and protects today
The antibody test is highly accurate in identifying SARS-CoV-2 antibodies and is designed to detect the spike protein receptor binding domain (S1RBD) on the surface of the SARS-CoV-2 virus which binds the virus to cells via a distinct human receptor (ACE2) found in lungs, heart, multiple organs and blood vessels.

Clinical reach with
~20,000 analyzers worldwide

Evidence shows antibodies to the spike protein are neutralizing – an important link to vaccine development

1. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.
2. Installed base of ADVIA Centaur XP, ADVIA Centaur XP+, ADVIA Centaur CP, Atellica Solution, Dimension Vista and Dimension EXL analyzers.
3. For samples collected ≥ 14 days after positive PCR result.
4. Based on results for the ADVIA Centaur COVID1 assay.
5. Depending on test mix and configuration using Atellica Solution.

HOOD00516203093539